- +1 858 909 0079
- +1 858 909 0057
- [email protected]
- +1 858 909 0079
- [email protected]
Cat# | Products (Recombinant protein) | Swiss Prot# | Size | Price (US$) | Order |
PL0497 | Recombinant protein-Plasmodium knowlesi-Erythrocyte-binding protein (a.a.61 to 460) | P22545 | 100 µg | 1195 | |
PL0498 | Recombinant protein-Plasmodium knowlesi SICA antigen (a.a.28 to 289) | B3L4E8 | 100 µg | 1195 | |
PL0499 | Recombinant protein-Plasmodium knowlesi Hypothetical malaria antigen (a.a.61 to 460) | B3L8Y1 | 100 µg | 1195 | |
PL0500 | Recombinant protein-Plasmodium knowlesi SICA-like antigen (a.a.21 to 247) | B3L0M5 | 100 µg | 1195 | |
PL0501 | Recombinant protein-Plasmodium knowlesi Transmission-blocking target antigen s230 (a.a.61 to 460) | B3L0V1 | 100 µg | 1195 | |
PL0502 | Recombinant protein-Plasmodium knowlesi Erythrocyte membrane-associated antigen (a.a.61 to 460) | B3L1U2 | 100 µg | 1195 | |
PL0503 | Recombinant protein-Plasmodium knowlesi Tryptophan-threonine rich antigen (a.a.60 to 440) | B3L0Y6 | 100 µg | 1195 | |
PL0504 | Recombinant protein-Plasmodium knowlesi 41-2 protein antigen- homolog (a.a.18 to 184) | B3LBB5 | 100 µg | 1195 | |
PL0505 | Recombinant protein-Plasmodium knowlesi Tryptophan-threonine-rich antigen (a.a.31 to 316) | B3L0Y5 | 100 µg | 1195 | |
PL0506 | Recombinant protein-Plasmodium knowlesi Liver stage antigen 3(a.a.61 to 460) | B3L0F6 | 100 µg | 1195 | |
PL0507 | Recombinant protein-Plasmodium knowlesi Asparagine-rich antigen (a.a.61 to 460) | B3L284 | 100 µg | 1195 | |
PL0508 | Recombinant protein-Plasmodium knowlesi Transmission-blocking target antigen Pfs230 (a.a.19 to 393) | B3KZX9 | 100 µg | 1195 | |
PL0509 | Recombinant protein-Plasmodium knowlesi Circumsporozoite-related antigen (a.a.22 to 133) | B3L519 | 100 µg | 1195 | |
PL0510 | Recombinant protein-Plasmodium knowlesi Malaria antigen (a.a.61 to 460) | B3L709 | 100 µg | 1195 | |
PL0511 | Recombinant protein-Plasmodium knowlesi-Herring worm-protein (a.a.31 to 400) | B3L0X7 | 100 µg | 1195 | |
PL0512 | Recombinant protein-Plasmodium knowlesi Blood-stage antigen 41-3(a.a.35 to 365) | B3LB64 | 100 µg | 1195 | |
PL0513 | Recombinant protein-Plasmodium knowlesi Transmission blocking target antigen (a.a.25 to 450) | B3L8C9 | 100 µg | 1195 | |
PL0514 | Recombinant protein-Plasmodium knowlesi Tryptophan-threonine-rich antigen (a.a.61 to 460) | B3L3F2 | 100 µg | 1195 | |
PL0515 | Recombinant protein-Plasmodium knowlesi Erythrocyte binding antigen (a.a.61 to 460) | B3L2E8 | 100 µg | 1195 | |
PL0516 | Recombinant protein-Plasmodium knowlesi Apical merozoite antigen 1 (a.a.61 to 460) | B3L5E1 | 100 µg | 1195 | |
PL0517 | Recombinant protein-Plasmodium knowlesi Rhoptry associated membrane antigen (a.a.61 to 460) | B3KZ17 | 100 µg | 1195 | |
PL0518 | Recombinant protein-Plasmodium knowlesi C-13 antigen (a.a.61 to 460) | B3L188 | 100 µg | 1195 | |
PL0519 | Recombinant protein-Plasmodium knowlesi Tryptophan-rich antigen (a.a.28 to 284) | B3L6R1 | 100 µg | 1195 | |
PL0520 | Recombinant protein-Plasmodium knowlesi SICA antigen (a.a.18 to 136) | B3LD42 | 100 µg | 1195 | |
PL0521 | Recombinant protein-Plasmodium knowlesi 205 kDa pk1(B+)1+ sicavar antigen (a.a. 18 to 221) | B3L1R4 | 100 µg | 1195 | |
PL0522 | Recombinant protein-Plasmodium knowlesi SICA-like antigen (a.a.53 to 311) | B3L3E6 | 100 µg | 1195 | |
PL0523 | Recombinant protein-Plasmodium knowlesi 66 kDa protective minor surface antigen (a.a.61 to 460) | P21303 | 100 µg | 1195 | |
RPL0497 | cDNA-Plasmodium knowlesi-Erythrocyte-binding protein (a.a.61 to 460) | P22545 | 2 µg | 2394 | |
RPL0498 | cDNA-Plasmodium knowlesi SICA antigen (a.a.28 to 289) | B3L4E8 | 2 µg | 1566 | |
RPL0499 | cDNA-Plasmodium knowlesi Hypothetical malaria antigen (a.a.61 to 460) | B3L8Y1 | 2 µg | 2394 | |
RPL0500 | cDNA-Plasmodium knowlesi SICA-like antigen (a.a.21 to 247) | B3L0M5 | 2 µg | 1356 | |
RPL0501 | cDNA-Plasmodium knowlesi Transmission-blocking target antigen s230 (a.a.61 to 460) | B3L0V1 | 2 µg | 2394 | |
RPL0502 | cDNA-Plasmodium knowlesi Erythrocyte membrane-associated antigen (a.a.61 to 460) | B3L1U2 | 2 µg | 2394 | |
RPL0503 | cDNA-Plasmodium knowlesi Tryptophan-threonine rich antigen (a.a.60 to 440) | B3L0Y6 | 2 µg | 2280 | |
RPL0504 | cDNA-Plasmodium knowlesi 41-2 protein antigen- homolog (a.a.18 to 184) | B3LBB5 | 2 µg | 996 | |
RPL0505 | cDNA-Plasmodium knowlesi Tryptophan-threonine-rich antigen (a.a.31 to 316) | B3L0Y5 | 2 µg | 1710 | |
RPL0506 | cDNA-Plasmodium knowlesi Liver stage antigen 3(a.a.61 to 460) | B3L0F6 | 2 µg | 2394 | |
RPL0507 | cDNA-Plasmodium knowlesi Asparagine-rich antigen (a.a.61 to 460) | B3L284 | 2 µg | 2394 | |
RPL0508 | cDNA-Plasmodium knowlesi Transmission-blocking target antigen Pfs230 (a.a.19 to 393) | B3KZX9 | 2 µg | 2244 | |
RPL0509 | cDNA-Plasmodium knowlesi Circumsporozoite-related antigen (a.a.22 to 133) | B3L519 | 2 µg | 800 | |
RPL0510 | cDNA-Plasmodium knowlesi Malaria antigen (a.a.61 to 460) | B3L709 | 2 µg | 2394 | |
RPL0511 | cDNA-Plasmodium knowlesi-Herring worm-protein (a.a.31 to 400) | B3L0X7 | 2 µg | 2214 | |
RPL0512 | cDNA-Plasmodium knowlesi Blood-stage antigen 41-3(a.a.35 to 365) | B3LB64 | 2 µg | 1980 | |
RPL0513 | cDNA-Plasmodium knowlesi Transmission blocking target antigen (a.a.25 to 450) | B3L8C9 | 2 µg | 2550 | |
RPL0514 | cDNA-Plasmodium knowlesi Tryptophan-threonine-rich antigen (a.a.61 to 460) | B3L3F2 | 2 µg | 2394 | |
RPL0515 | cDNA-Plasmodium knowlesi Erythrocyte binding antigen (a.a.61 to 460) | B3L2E8 | 2 µg | 2394 | |
RPL0516 | cDNA-Plasmodium knowlesi Apical merozoite antigen 1 (a.a.61 to 460) | B3L5E1 | 2 µg | 2394 | |
RPL0517 | cDNA-Plasmodium knowlesi Rhoptry associated membrane antigen (a.a.61 to 460) | B3KZ17 | 2 µg | 2394 | |
RPL0518 | cDNA-Plasmodium knowlesi C-13 antigen (a.a.61 to 460) | B3L188 | 2 µg | 2394 | |
RPL0519 | cDNA-Plasmodium knowlesi Tryptophan-rich antigen (a.a.28 to 284) | B3L6R1 | 2 µg | 1536 | |
RPL0520 | cDNA-Plasmodium knowlesi SICA antigen (a.a.18 to 136) | B3LD42 | 2 µg | 708 | |
RPL0521 | cDNA-Plasmodium knowlesi 205 kDa pk1(B+)1+ sicavar antigen (a.a. 18 to 221) | B3L1R4 | 2 µg | 1218 | |
RPL0522 | cDNA-Plasmodium knowlesi SICA-like antigen (a.a.53 to 311) | B3L3E6 | 2 µg | 1548 | |
RPL0523 | cDNA-Plasmodium knowlesi 66 kDa protective minor surface antigen (a.a.61 to 460) | P21303 | 2 µg | 2394 |
Plasmodium knowlesi cDNA and recombinant antigen
Plasmodium knowlesi is a zoonotic malaria parasite that can infect both macaque monkeys and humans. Several key proteins produced by this parasite play critical roles in pathogenesis and may be important targets for drug and vaccine development.
One such protein is the Erythrocyte-binding protein, which is involved in the invasion of erythrocytes by the parasite. SICA antigen and SICA-like antigen are also critical in erythrocyte invasion, while the hypothetical malaria antigen and Blood-stage antigen 41-3 are involved in the development of the parasite within the erythrocytes.
The Transmission-blocking target antigen s230 is involved in blocking the transmission of the parasite between human hosts and mosquitoes, while the Tryptophan-threonine rich antigen is thought to be involved in immune evasion. The 41-2 protein antigen- homolog is another key protein in the pathogenesis of P. knowlesi.
Liver stage antigen 3 and Pfs230 are critical in the development of the parasite in the liver and may be important targets for liver-stage vaccines. Additionally, Circumsporozoite-related antigen, Malaria antigen, Erythrocyte binding antigen, Apical merozoite antigen 1, and C-13 antigen all play critical roles in the pathogenesis of P. knowlesi.
Understanding the complex protein structures and roles of Plasmodium knowlesi is crucial in developing effective treatment and prevention strategies for malaria. By identifying key proteins and their functions, researchers can work to develop targeted therapies and vaccines to combat this deadly disease.
The use of cDNA and recombinant antigens from P. knowlesi has become an important tool in the diagnosis of human malaria caused by this species. cDNA and recombinant antigens can be used to detect the presence of the parasite in the blood, providing a more specific diagnosis than traditional microscopy. Additionally, recombinant antigens can be used to develop more specific and sensitive immunoassays, such as enzyme-linked immunosorbent assays (ELISAs) and lateral flow assays, for the rapid and specific detection of P. knowlesi in a clinical sample. Thus, the use of cDNA and recombinant antigens from P. knowlesi has enabled the more accurate and timely diagnosis of human malaria caused by this species.
The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.
Get the Latest News and Updates by Email
6393 Nancy Ridge Dr. Suite A
San Diego, CA 92121 USA
Fax: +1-858-909-0057
Get the Latest News and Updates by Email
© 2023 Bioclone Inc. All Rights Reserved.
Magnetic Beads Make Things Simple
